Lori Melançon | Vice President of Corporate Communications and Investor Relations |
Pablo Cagnoni | Chief Executive Officer |
Christina Coughlin | Chief Medical Officer |
Laurence Turka | Chief Scientific Officer |
Andy Oh | Chief Financial Officer |
Michael Yee | Jefferies |
Michael Schmidt | Guggenheim |
Jonathan Chang | SVB Leerink |
Matthew Harrison | Morgan Stanley |
Jessica Fye | JPMorgan |
Good morning and welcome to the Rubius Therapeutics Fourth Quarter and Full Year 2019 Financial Results and Strategic Update Teleconference and Webcast. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. Please be aware that today’s webcast is being recorded.
I would now like to introduce the first speaker, Lori Melançon, Vice President of Corporate Communications and Investor Relations.